Group Leader Statistics, Principal Scientist II
Tim joined Metrum in 2019, bringing 12 years of experience in the pharmaceutical industry. He attained his Ph.D. in Statistics from the University of Queensland, where he applied optimal design methods to PK/PD models. He then worked at Eli Lilly and Company in the PK/PD & Pharmacometrics department, using modeling and simulation to inform decision making in all phases of drug development across a range of therapeutic areas.
November 13, 2024
Presented at ACoP 2024. The aim was to provide a simple, reproducible, and traceable method for generating parameter tables in R for NONMEM. models. Attainedvia a new package (pmparams): a stable and easy-to-use tool intended to integrate with, and extend the functionality of, existing packages in the Metrum Research Group Ecosystem (MeRGE)
September 5, 2024
This study characterizes the population pharmacokinetics (PK) of vedolizumab in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for graft-versus-host disease (GvHD) prophylaxis. The analysis identified body weight and albumin levels as significant predictors of vedolizumab clearance, though the covariates studied had no clinically meaningful effect on its overall PK. The findings offer important insights into dosing strategies for vedolizumab in this patient population.
July 8, 2024
Presented at PAGE 2024. The bbr.bayes package reduces much of the friction associated with a Bayesian pharmacometrics analysis in NONMEM® and promotes good practice applications.Â